273 related articles for article (PubMed ID: 37091188)
1. Dose optimization strategy of the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib for chronic myeloid leukemia: From clinical trials to real-life settings.
Cheng F; Li Q; Cui Z; Hong M; Li W; Zhang Y
Front Oncol; 2023; 13():1146108. PubMed ID: 37091188
[TBL] [Abstract][Full Text] [Related]
2. Dose Optimization of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A New Therapeutic Challenge.
Iurlo A; Cattaneo D; Bucelli C; Breccia M
J Clin Med; 2021 Feb; 10(3):. PubMed ID: 33535564
[TBL] [Abstract][Full Text] [Related]
3. Treatment-free remission after discontinuation of imatinib, dasatinib, and nilotinib in patients with chronic myeloid leukemia.
Han JJ
Blood Res; 2023 Apr; 58(S1):S58-S65. PubMed ID: 37026381
[TBL] [Abstract][Full Text] [Related]
4. Current status of ABL tyrosine kinase inhibitors stop studies for chronic myeloid leukemia.
Kimura S
Stem Cell Investig; 2016; 3():36. PubMed ID: 27583255
[TBL] [Abstract][Full Text] [Related]
5. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
[TBL] [Abstract][Full Text] [Related]
6. Low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study.
Cayssials E; Torregrosa-Diaz J; Gallego-Hernanz P; Tartarin F; Systchenko T; Maillard N; Desmier D; Machet A; Fleck E; Corby A; Motard C; Denis G; Herbelin A; Gombert JM; Roy L; Ragot S; Leleu X; Guilhot F; Chomel JC
Cancer; 2020 Aug; 126(15):3438-3447. PubMed ID: 32459375
[TBL] [Abstract][Full Text] [Related]
7. [What is the best treatment for chronic-phase CML?].
Sakaida E
Rinsho Ketsueki; 2021; 62(8):1012-1023. PubMed ID: 34497187
[TBL] [Abstract][Full Text] [Related]
8. Treatment-Free Remission in Chronic Myeloid Leukemia Patients Treated With Low-Dose TKIs: A Feasible Option Also in the Real-Life. A Campus CML Study.
Iurlo A; Cattaneo D; Artuso S; Consonni D; Abruzzese E; Binotto G; Bocchia M; Bonifacio M; Castagnetti F; Galimberti S; Gozzini A; Iezza M; Latagliata R; Luciano L; Maggi A; Miggiano MC; Pregno P; Rege-Cambrin G; Russo S; Scortechini AR; Tafuri A; Tiribelli M; Fava C; Rosti G; Foa R; Breccia M; Saglio G
Front Oncol; 2022; 12():839915. PubMed ID: 35311109
[TBL] [Abstract][Full Text] [Related]
9. Treatment free remission (TFR) after second-generation tyrosine kinase inhibitors (2G-TKIs) treatment in chronic myeloid leukemia (CML): from feasibility to safety.
Laganà A; Scalzulli E; Bisegna ML; Carmosino I; Ielo C; Costa A; Torrieri L; Totaro M; Martelli M; Breccia M
Expert Opin Drug Saf; 2024 Jun; ():1-11. PubMed ID: 38873693
[TBL] [Abstract][Full Text] [Related]
10. Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study.
Iurlo A; Cattaneo D; Consonni D; Castagnetti F; Miggiano MC; Binotto G; Bonifacio M; Rege-Cambrin G; Tiribelli M; Lunghi F; Gozzini A; Pregno P; Abruzzese E; Capodanno I; Bucelli C; Pizzuti M; Artuso S; Iezza M; Scalzulli E; La Barba G; Maggi A; Russo S; Elena C; Scortechini AR; Tafuri A; Latagliata R; Caocci G; Bocchia M; Galimberti S; Luciano L; Fava C; Foà R; Saglio G; Rosti G; Breccia M
Front Pharmacol; 2023; 14():1154377. PubMed ID: 37033642
[TBL] [Abstract][Full Text] [Related]
11. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
12. Sequential use of second-generation tyrosine kinase inhibitors following imatinib therapy in pediatric chronic myeloid leukemia: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group.
Kurosawa H; Tanizawa A; Muramatsu H; Tono C; Watanabe A; Shima H; Ito M; Yuza Y; Hamamoto K; Hotta N; Okada M; Saito AM; Manabe A; Mizutani S; Adachi S; Horibe K; Ishii E; Shimada H
Pediatr Blood Cancer; 2018 Dec; 65(12):e27368. PubMed ID: 30084127
[TBL] [Abstract][Full Text] [Related]
13. [Chronic myeloid leukemia: aiming for treatment free remission].
Kimura S
Rinsho Ketsueki; 2021; 62(6):572-581. PubMed ID: 34219083
[TBL] [Abstract][Full Text] [Related]
14. [Observational study of chronic myeloid leukemia Chinese patients who discontinued tyrosine kinase inhibitors in the real-world].
Zhao HF; Yang YF; Liu BC; Li WM; Xu N; Liu XL; Jiang Q; Dang HB; Liang LX; Zhang Y; Song YP
Zhonghua Xue Ye Xue Za Zhi; 2022 Aug; 43(8):636-643. PubMed ID: 36709147
[No Abstract] [Full Text] [Related]
15. [Prevalence of Adverse Effects of Tyrosine Kinase Inhibitors Used in Management of Chronic Myeloid Leukemia at Sidi Bel-Abbès University Hospital Center].
Matmour D; Si-Ali N; Benmehimda NC; Beloufa S; Belfrak F; Mahi E; Merad Y; Toumi H; Benlazar M
Ann Pharm Fr; 2022 Nov; 80(6):932-942. PubMed ID: 35469781
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy and tolerability of front-line treatments for newly diagnosed chronic-phase chronic myeloid leukemia: an update network meta-analysis.
Tang L; Zhang H; Peng YZ; Li CG; Jiang HW; Xu M; Mei H; Hu Y
BMC Cancer; 2019 Aug; 19(1):849. PubMed ID: 31462241
[TBL] [Abstract][Full Text] [Related]
17. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Yilmaz M; Lahoti A; O'Brien S; Nogueras-González GM; Burger J; Ferrajoli A; Borthakur G; Ravandi F; Pierce S; Jabbour E; Kantarjian H; Cortes JE
Cancer; 2015 Nov; 121(21):3894-904. PubMed ID: 26217876
[TBL] [Abstract][Full Text] [Related]
18. A Real-World Evidence-Based Study of Long-Term Tyrosine Kinase Inhibitors Dose Reduction or Discontinuation in Patients with Chronic Myeloid Leukaemia.
Martín Roldán A; Sánchez Suárez MDM; Alarcón-Payer C; Jiménez Morales A; Puerta Puerta JM
Pharmaceutics; 2023 Apr; 15(5):. PubMed ID: 37242605
[TBL] [Abstract][Full Text] [Related]
19. Severe adverse events by tyrosine kinase inhibitors decrease survival rates in patients with newly diagnosed chronic-phase chronic myeloid leukemia.
Ota S; Matsukawa T; Yamamoto S; Ito S; Shindo M; Sato K; Kondo T; Kohda K; Sakai H; Mori A; Takahashi T; Ikeda H; Kuroda H; Haseyama Y; Yamamoto M; Sarashina T; Yoshida M; Kobayashi R; Nishio M; Ishihara T; Hirayama Y; Kakinoki Y; Kobayashi H; Fukuhara T; Imamura M; Kurosawa M
Eur J Haematol; 2018 Jul; 101(1):95-105. PubMed ID: 29660177
[TBL] [Abstract][Full Text] [Related]
20. Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial.
Atallah E; Schiffer CA; Radich JP; Weinfurt KP; Zhang MJ; Pinilla-Ibarz J; Kota V; Larson RA; Moore JO; Mauro MJ; Deininger MWN; Thompson JE; Oehler VG; Wadleigh M; Shah NP; Ritchie EK; Silver RT; Cortes J; Lin L; Visotcky A; Baim A; Harrell J; Helton B; Horowitz M; Flynn KE
JAMA Oncol; 2021 Jan; 7(1):42-50. PubMed ID: 33180106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
